{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:08:35Z","timestamp":1790863715028,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:p>\n            The chronic inflammatory state of rheumatoid arthritis and other inflammatory arthropathies, such as ankylosing spondylitis and psoriatic arthritis, contributes to the accelerated atherosclerosis associated with these conditions. This study evaluates the effect of treatment with tumor necrosis factor (TNF)-\u03b1 antagonists on arterial stiffness in patients with inflammatory arthropathies. A total of 60 patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis and clinical indication for anti\u2013TNF-\u03b1 therapy were included. Thirty-five patients started with anti\u2013TNF-\u03b1 therapy and were compared with a nontreatment group of 25 patients. Aortic stiffness (aortic pulse wave velocity), augmentation index, and disease activity were assessed at baseline and after 3 months. Aortic pulse wave velocity (mean\u00b1SD) was reduced in the treatment group but not in the control group (\u22120.50\u00b10.78 m\/s versus 0.05\u00b10.54 m\/s, respectively;\n            <jats:italic>P<\/jats:italic>\n            =0.002). Concomitantly, C-reactive protein and the disease activity score were reduced in the treatment group (\u22129.3\u00b120.2 mg\/L [\n            <jats:italic>P<\/jats:italic>\n            &lt;0.001] and \u22120.74\u00b10.91 [\n            <jats:italic>P<\/jats:italic>\n            =0.004]). Augmentation index remained unchanged in both groups (0.1\u00b17.1% versus \u22121.0\u00b15.8%, respectively;\n            <jats:italic>P<\/jats:italic>\n            =0.53). In a multivariate linear regression model, only treatment with TNF-\u03b1 antagonist and change in mean arterial pressure predicted alterations in aortic pulse wave velocity. In summary, anti\u2013TNF-\u03b1 therapy improved aortic stiffness in patients with inflammatory arthropathies. These findings support the idea that anti-inflammatory treatment has a favorable effect on cardiovascular risk in patients with inflammatory arthropathies.\n          <\/jats:p>","DOI":"10.1161\/hypertensionaha.109.143982","type":"journal-article","created":{"date-parts":[[2009,12,29]],"date-time":"2009-12-29T02:09:48Z","timestamp":1262052588000},"page":"333-338","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":134,"title":["Tumor Necrosis Factor-\u03b1 Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies"],"prefix":"10.1161","volume":"55","author":[{"given":"Kristin","family":"Angel","sequence":"first","affiliation":[{"name":"From the Department of Cardiology (K.A., H.L.G., D.A.), Oslo University Hospital Aker, Oslo, Norway; Department of Rheumatology (S.A.P., P.M., T.K.K.), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo (T.K.K., D.A.), Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sella Aarrestad","family":"Provan","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology (K.A., H.L.G., D.A.), Oslo University Hospital Aker, Oslo, Norway; Department of Rheumatology (S.A.P., P.M., T.K.K.), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo (T.K.K., D.A.), Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne L\u00f8vdahl","family":"Gulseth","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology (K.A., H.L.G., D.A.), Oslo University Hospital Aker, Oslo, Norway; Department of Rheumatology (S.A.P., P.M., T.K.K.), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo (T.K.K., D.A.), Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Mowinckel","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology (K.A., H.L.G., D.A.), Oslo University Hospital Aker, Oslo, Norway; Department of Rheumatology (S.A.P., P.M., T.K.K.), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo (T.K.K., D.A.), Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore Kristian","family":"Kvien","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology (K.A., H.L.G., D.A.), Oslo University Hospital Aker, Oslo, Norway; Department of Rheumatology (S.A.P., P.M., T.K.K.), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo (T.K.K., D.A.), Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Atar","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology (K.A., H.L.G., D.A.), Oslo University Hospital Aker, Oslo, Norway; Department of Rheumatology (S.A.P., P.M., T.K.K.), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo (T.K.K., D.A.), Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735"},{"key":"e_1_3_2_2_2","first-page":"2167","volume":"33","year":"2006","unstructured":"Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006; 33: 2167\u20132172.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000054612.26458.b2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10089"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20878"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009302"},{"key":"e_1_3_2_8_2","first-page":"183","volume":"1","year":"2005","unstructured":"Hadi HA, Carr CS, Al SJ. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005; 1: 183\u2013198.","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl254"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10269"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.601641"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.007740"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei145"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086777"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22884"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken198"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20080196"},{"key":"e_1_3_2_19_2","first-page":"1213","volume":"32","year":"2005","unstructured":"Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005; 32: 1213\u20131218.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000037521.71373.44"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086157"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126097-200306000-00006"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.38.4.932"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816121-00033"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Hosmer D Lemeshow W. Applied Logistic Regression. 2nd ed. New York NY: John Wiley and Sons; 2000.","DOI":"10.1002\/0471722146"},{"key":"e_1_3_2_29_2","unstructured":"Cohen J. Statistical Power Analysis for Behavioral Sciences. 2nd ed. Hillsdale NJ: Laurence Erlbaum Associates; 1988."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0605-8"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep251"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei033"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.04.031"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.535435"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.109.190108"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707402"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"R5.","DOI":"10.1186\/ar428","volume":"4","year":"2002","unstructured":"Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002; 4: R5.","journal-title":"Arthritis Res"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.38.3.399"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken159"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16449-0"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.076"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066191"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092171"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08213-2"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.109.143982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:22:10Z","timestamp":1715592130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.109.143982"}},"subtitle":["A Controlled Study"],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.109.143982"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.109.143982","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"2009-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}